Table 1

Characteristics of participants in included studies for bacterial pneumonia and Pneumocystis jiroveci pneumonia.

Reference

Number. of participants

Men (%)

Mean/median age(SD) in years

Smokers (%)

Non-smokers (%)

Mean/median CD4+ count

Use of HAART


Bacterial pneumonia


[12]

40

75

Median 30 to 40

NR

NR

NR

Pre HAART era

[21]

867

99

Mean 50 (10)

63%

22% former smokers,15% never smokers

NR

Post-HAART era

[13]

509

100

Median 30

80%

20% non-smokers

177 cells/μL

Post-HAART era

[23]

5472

73

Median 43

41%

25% former, 34% never smokers

>350 cells/μL

Post-HAART era

[14]

1130

NR

NR

NR

NR

NR

Pre-HAART era

[15]

885

0 (all female)

Mean 36

76%

24%

NR

Pre and Post HAART era

[16]

1203

77

Mean 36

66% unknown orcurrent smokers

34% currently not smoking

279 cells/μL

Post-HAART era

[17]

300

56

Mean 37 (7)

92%

8% non-smokers

327 cells/μL

Post-HAART era

[18]

285

NR

Mean 34 (8)

55%

45% non-smokers

182 cells/μL

Pre-HAART era


Bacterial pneumonia and Pneumocystis jiroveci pneumonia


19]

3221

83

Mean 37

57%

19% former smokers,24%, never smoker

327 cells/μL

Pre-HAART era

[20]

232

100

Median 36 to 38

46%

54%

NR

Pre-HAART era

[25]

521

58

Mean 42 (9)

63%

12% former smokers,25% never smokers

172 cells/μL

Post-HAART era


Pneumocystis jiroveci pneumonia only


[22]

2499

100

NR

39%

61%

>200 cells/μL

Pre-HAART era

[24]

54

59

Mean 40

NR

NR

257 cells/μL

Post-HAART era


HAART: highly active antiretroviral treatments; NA: not applicable; NR: not reported.

De et al. BMC Medicine 2013 11:15   doi:10.1186/1741-7015-11-15

Open Data